Atherosclerosis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Atherosclerosis – Pipeline Review, H2 2016’, provides an overview of the Atherosclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Atherosclerosis

The report reviews pipeline therapeutics for Atherosclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Atherosclerosis therapeutics and enlists all their major and minor projects

The report assesses Atherosclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Atherosclerosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Atherosclerosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ache Laboratorios Farmaceuticos S/A

advanceCor GmbH

AFFiRiS AG

Akcea Therapeutics Inc

Amgen Inc.

Arisaph Pharmaceuticals, Inc.

ARMO Biosciences, Inc.

Artery Therapeutics, Inc.

Athera Biotechnologies AB

Cardax, Inc.

Cerenis Therapeutics Holding SA

ChemoCentryx, Inc.

CohBar, Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

DoNatur GmbH

Dybly AG

GenKyoTex S.A.

HitGen LTD

Jenrin Discovery, Inc.

Kang Stem Biotech Co., Ltd.

KineMed, Inc.

Kowa Company, Ltd.

La Jolla Pharmaceutical Company

Lead Discovery Center GmbH

LipimetiX Development Inc

Merck & Co., Inc.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Resverlogix Corp.

The Medicines Company

Therapix Biosciences Ltd.

Tolerys SA

Unity Biotechnology, Inc.

Vascular Biogenics Ltd.

Vericel Corporation

Vicore Pharma AB

Vitae Pharmaceuticals, Inc.

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Atherosclerosis Overview 7

Therapeutics Development 8

Atherosclerosis - Therapeutics under Development by Companies 10

Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 13

Atherosclerosis - Pipeline Products Glance 15

Atherosclerosis - Products under Development by Companies 18

Atherosclerosis - Products under Investigation by Universities/Institutes 22

Atherosclerosis - Companies Involved in Therapeutics Development 24

Atherosclerosis - Therapeutics Assessment 63

Drug Profiles 77

Atherosclerosis - Dormant Projects 210

Atherosclerosis - Discontinued Products 222

Atherosclerosis - Product Development Milestones 225

Appendix 241

List of Tables

List of Tables

Number of Products under Development for Atherosclerosis, H2 2016 18

Number of Products under Development for Atherosclerosis – Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Development by Companies, H2 2016 (Contd..1) 21

Number of Products under Development by Companies, H2 2016 (Contd..2) 22

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Late Stage Development, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Development, H2 2016 27

Products under Development by Companies, H2 2016 28

Products under Development by Companies, H2 2016 (Contd..1) 29

Products under Development by Companies, H2 2016 (Contd..2) 30

Products under Development by Companies, H2 2016 (Contd..3) 31

Products under Investigation by Universities/Institutes, H2 2016 32

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 33

Atherosclerosis – Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 34

Atherosclerosis – Pipeline by advanceCor GmbH, H2 2016 35

Atherosclerosis – Pipeline by AFFiRiS AG, H2 2016 36

Atherosclerosis – Pipeline by Akcea Therapeutics Inc, H2 2016 37

Atherosclerosis – Pipeline by Amgen Inc., H2 2016 38

Atherosclerosis – Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 39

Atherosclerosis – Pipeline by ARMO Biosciences, Inc., H2 2016 40

Atherosclerosis – Pipeline by Artery Therapeutics, Inc., H2 2016 41

Atherosclerosis – Pipeline by Athera Biotechnologies AB, H2 2016 42

Atherosclerosis – Pipeline by Cardax, Inc., H2 2016 43

Atherosclerosis – Pipeline by Cerenis Therapeutics Holding SA, H2 2016 44

Atherosclerosis – Pipeline by ChemoCentryx, Inc., H2 2016 45

Atherosclerosis – Pipeline by CohBar, Inc., H2 2016 46

Atherosclerosis – Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 47

Atherosclerosis – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 48

Atherosclerosis – Pipeline by DoNatur GmbH, H2 2016 49

Atherosclerosis – Pipeline by Dybly AG, H2 2016 50

Atherosclerosis – Pipeline by GenKyoTex S.A., H2 2016 51

Atherosclerosis – Pipeline by HitGen LTD, H2 2016 52

Atherosclerosis – Pipeline by Jenrin Discovery, Inc., H2 2016 53

Atherosclerosis – Pipeline by Kang Stem Biotech Co., Ltd., H2 2016 54

Atherosclerosis – Pipeline by KineMed, Inc., H2 2016 55

Atherosclerosis – Pipeline by Kowa Company, Ltd., H2 2016 56

Atherosclerosis – Pipeline by La Jolla Pharmaceutical Company, H2 2016 57

Atherosclerosis – Pipeline by Lead Discovery Center GmbH, H2 2016 58

Atherosclerosis – Pipeline by LipimetiX Development Inc, H2 2016 59

Atherosclerosis – Pipeline by Merck & Co., Inc., H2 2016 60

Atherosclerosis – Pipeline by Omeros Corporation, H2 2016 61

Atherosclerosis – Pipeline by Otsuka Holdings Co., Ltd., H2 2016 62

Atherosclerosis – Pipeline by Resverlogix Corp., H2 2016 63

Atherosclerosis – Pipeline by The Medicines Company, H2 2016 64

Atherosclerosis – Pipeline by Therapix Biosciences Ltd., H2 2016 65

Atherosclerosis – Pipeline by Tolerys SA, H2 2016 66

Atherosclerosis – Pipeline by Unity Biotechnology, Inc., H2 2016 67

Atherosclerosis – Pipeline by Vascular Biogenics Ltd., H2 2016 68

Atherosclerosis – Pipeline by Vericel Corporation, H2 2016 69

Atherosclerosis – Pipeline by Vicore Pharma AB, H2 2016 70

Atherosclerosis – Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 71

Atherosclerosis – Pipeline by XBiotech Inc, H2 2016 72

Assessment by Monotherapy Products, H2 2016 73

Assessment by Combination Products, H2 2016 74

Number of Products by Stage and Target, H2 2016 76

Number of Products by Stage and Mechanism of Action, H2 2016 80

Number of Products by Stage and Route of Administration, H2 2016 84

Number of Products by Stage and Molecule Type, H2 2016 86

Atherosclerosis – Dormant Projects, H2 2016 220

Atherosclerosis – Dormant Projects (Contd..1), H2 2016 221

Atherosclerosis – Dormant Projects (Contd..2), H2 2016 222

Atherosclerosis – Dormant Projects (Contd..3), H2 2016 223

Atherosclerosis – Dormant Projects (Contd..4), H2 2016 224

Atherosclerosis – Dormant Projects (Contd..5), H2 2016 225

Atherosclerosis – Dormant Projects (Contd..6), H2 2016 226

Atherosclerosis – Dormant Projects (Contd..7), H2 2016 227

Atherosclerosis – Dormant Projects (Contd..8), H2 2016 228

Atherosclerosis – Dormant Projects (Contd..9), H2 2016 229

Atherosclerosis – Dormant Projects (Contd..10), H2 2016 230

Atherosclerosis – Dormant Projects (Contd..11), H2 2016 231

Atherosclerosis – Discontinued Products, H2 2016 232

Atherosclerosis – Discontinued Products (Contd..1), H2 2016 233

Atherosclerosis – Discontinued Products (Contd..2), H2 2016 234

List of Figures

List of Figures

Number of Products under Development for Atherosclerosis, H2 2016 18

Number of Products under Development for Atherosclerosis – Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Investigation by Universities/Institutes, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Products, H2 2016 27

Assessment by Monotherapy Products, H2 2016 73

Number of Products by Top 10 Targets, H2 2016 75

Number of Products by Stage and Top 10 Targets, H2 2016 75

Number of Products by Top 10 Mechanism of Actions, H2 2016 79

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 79

Number of Products by Routes of Administration, H2 2016 83

Number of Products by Stage and Routes of Administration, H2 2016 83

Number of Products by Top 10 Molecule Types, H2 2016 85

Number of Products by Stage and Top 10 Molecule Types, H2 2016 85

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports